Company: Mission Therapeutics
Job title: Chief Scientific Officer
Paul has more than 15 years of experience in translational research and early clinical development. Before joining Mission as Medical Director for CNS, Paul worked as a Clinical Science Director at ONO Pharma UK, leading clinical development of multiple early phase assets across a variety of indications including inflammatory pain, portal hypertension, whilst driving translational strategies for preclinical programs. Prior to this, Paul spent 12 years at GlaxoSmithKline, transitioning from laboratory biomarker research, through experimental medicine study leadership, to leading global project teams as Director of Discovery Medicine in the Neurology TA.
Paul is a member of the British Pharmacological Society and American Academy of Neurology, and is an industry tools consortium member with the Michael J Fox Foundation.
Paul holds an MBiochem from the University of Oxford and a PhD from UCL.
Discussion/Q&A 3:00 pm
day: Day Two
Deubiquitylating (DUB) Enzyme Targeting for Treatment of Human Disease 2:00 pm
DUBs antagonise action of ubiquitin ligases – inhibiting the inhibitor DUB specificity/localization informs target/indication selection – USP30 as an example DUB/substrate/ligase partnership data mining for new opportunities DUB inhibition opportunities exist in neurodegenerative diseaseRead more
day: Day Two